Patrick Forde
@FordePatrick
Lung cancer & Mesothelioma @HopkinsThoracic @HopkinsKimmel Immunotherapy believer. 🇮🇪 🇺🇸
ID:1141736655616978944
https://www.hopkinsmedicine.org/profiles/results/directory/profile/0554010/patrick-forde 20-06-2019 15:56:45
2,7K Tweets
5,4K Followers
2,0K Following
Kicking Saturday morning off at #AILCC24 Patrick Forde gives a masterful overview of peri-operative #immunotherapy in NSCLC
➡️ pCR highly predictive of outcome
➡️ liver might be a sanctuary site for relapse
➡️ clear need to optimise treatment duration
IASLC
#AILCC24
Starting day 2 with Patrick Forde on periop chemoIO in nsclc. Compared to his talk 2 yrs ago, major advances include:
- periop trials now show OS benefit (KN671)
- pCR an emerging surrogate endpt
- ICER/financial evaluations are key
IASLC #IrishLungCancerAlliance #LCSM
Great overview on liquid biopsy from Prof Natasha Leighl from University Health Network at #AILCC24
Makes the argument for liquid biopsy up front or a concurrent approach.
#IrishLungCancerAlliance IASLC
Pre 2024 Ireland Lung Cancer Conference exercise program with Drs. Dr. Julie Brahmer & Jarushka Naidoo ! #AILCC24 #lcsm 🇮🇪
Wonderful to see our #liquidbiopsies research highlighted in the #AACR24 #precisiononcology special series!
Read the open access Clinical Cancer Research study: aacrjournals.org/clincancerres/…
AACR Johns Hopkins Thoracic Oncology Johns Hopkins Medicine Lavanya Sivapalan Joseph Murray
The Molecular OncologyLab is on the way to #AACR24 ! Hope to see everyone at our presentations & poster sessions covering #liquidbiopsies #cancergenomics , #Immunotherapy #PrecisionOncology ! + celebrating 3⃣ scholar-in-training awards! AACR Blair Landon Lavanya Sivapalan Maria Fatteh
We are absolutely delighted with this appointment and are very looking forward to the years ahead! Congratulations Gerry Hanna ! #SLRON RadiationTherapyTCD Trinity St James's Cancer Institute Irish Cancer Society Dublin Midlands Hospital Group NCCP
Most viewed in the last 7 days from JAMA Oncology:
Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemoimmunotherapy?
ja.ma/3TELLl3
Calling all medical students in their 4th or 5th year 📢 Dive into the world of #medicaloncology with our ESMO Courses on #MedicalOncology tailored just for you. All application info 👉 ow.ly/cwTX50R3b1e
#ESMOStudents Andres Cervantes Matteo Lambertini, MD PhD Jon Lim